NanoViricides plans Phase II trial of NV-387 for measles

• NanoViricides announced Nov. 10, 2026, it is developing a Phase II trial protocol for NV-387 in measles, targeting FDA review.
• Already reported animal studies showed antiviral activity against measles; a completed juvenile mouse study found no treatment-related toxicity.
• NV-387 remains investigational, with no FDA approval for any disease; it is already in Phase II trials for Ebola and mpox.
• FDA orphan drug designation offers potential tax credits, fee exemptions and seven years of market exclusivity following approval.
• Rare pediatric disease designation could yield a transferable priority review voucher upon successful marketing approval, subject to required conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611100845ACCESSWRNAPR_____1249304) on November 10, 2026, and is solely responsible for the information contained therein.